NCT05588609 2025-09-18
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Merus B.V.
Phase 2 Terminated
Clinical Trials
4 trialsNCT00748709 2025-02-11
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
Phase 2 Terminated
NCT01345669 2017-12-07
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Boehringer Ingelheim
Phase 3 Terminated
NCT02695290 2017-09-18
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
Boehringer Ingelheim
Phase 4 Terminated